# A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

> **NCT04158700** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** LY3200882
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04158700
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-05
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The withdrawal is due to a strategic realignment and is not related to any particular safety or efficacy concern.
- **Last updated:** 2020-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158700, "A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT04158700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*